A new analysis of the antibiotic pipeline indicates there aren’t enough antibiotics in development to meet current and anticipated patient needs. The analysis, published this week by the Pew Charitable Trusts’ antibiotic resistance project, found that 41 new antibiotics with potential to treat serious infections are currently in various phases of clinical development, and four have been approved since June 2019. But while the antibiotics in development address many of the antibiotic-resistant pathogens that have been prioritized by the US Centers for Disease Control and Prevention and the World Health Organization (WHO), only a fraction will be approved. “We still have too few antibiotics for the superbugs that are out there today, and the ones we can anticipate…as they continue to mutate and evade our current stock of antibiotics,” said Wes Kim, PhD, MBA, senior officer with Pew’s antibiotic resistance project.

 

CC0 Creative Commons, Pexels

Trinks’ Images

Read more at CIDRAP…